Ignite Creation Date:
2025-12-25 @ 12:08 AM
Ignite Modification Date:
2025-12-25 @ 12:08 AM
Study NCT ID:
NCT05164458
Status:
RECRUITING
Last Update Posted:
2023-12-28
First Post:
2021-11-25
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Safety and Efficacy of IBI389 Single Agent, and in Combination With Sintilimab, in Patients With Advanced Malignancies
Sponsor:
Innovent Biologics (Suzhou) Co. Ltd.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2022-03-22
Start Date Type:
ACTUAL
Primary Completion Date:
2024-04-30
Primary Completion Date Type:
ESTIMATED
Completion Date:
2024-09-30
Completion Date Type:
ESTIMATED
First Submit Date:
2021-11-25
First Submit QC Date:
None
Study First Post Date:
2021-12-20
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2023-12-27
Last Update Post Date:
2023-12-28
Last Update Post Date Type:
ACTUAL